August 15th 2025, 4:00pm
By Ryan Scott
Cancer treatments can speed up aging in survivors, according to research, which can contribute to a person's risk for conditions like heart disease.
August 15th 2025, 3:00pm
By Alex Biese
The FDA has granted fast track designation to HLD-0915 for metastatic castration-resistant prostate cancer.
August 15th 2025, 1:00pm
By Dr. Patrick Wen
The accelerated approval of Modeyso for diffuse midline glioma with an H3 K27M mutation, is a step in the right direction but more work remains.
August 14th 2025, 9:00pm
Breast cancer survivor and researcher LaShae Rolle studies how individualized strength training during chemo boosts physical, mental and emotional health.
August 14th 2025, 8:00pm
By Dr. Jim Omel
Dr. Jim Omel, who was diagnosed with multiple myeloma in 1997, explained how the treatment landscape has changed over nearly 30 years.
August 14th 2025, 7:00pm
By Spencer Feldman
More than half of patients with myelofibrosis and low platelets treated with Vonjo saw platelets rise 58% and hemoglobin levels improve.
August 14th 2025, 5:00pm
By Martha Carlson
Living with stage 4 cancer taught me the power of community; connecting with others provides guidance, support, and hope in an often-lonely journey.
August 14th 2025, 4:00pm
Dr. Jacob Sands explained that he believes patients should be having more personalized, nuanced conversations with their oncologists.
August 14th 2025, 3:00pm
Real-world data show that Enhertu benefits those with HR+ breast cancer, whereas Trodelvy is effective as an initial treatment for HER2-null/HER2– disease.
August 14th 2025, 1:00pm
By Bryan Lewis
There are many reliable resources available to patients with kidney cancer, as well as their families and caregivers.
August 13th 2025, 9:00pm
Dr. Zev Wainberg of UCLA recently spoke with CURE about trial results concerning the cancer vaccine ELI-002 2P.
August 13th 2025, 8:00pm
Follicular lymphoma survivor Troy Anderson credited acupuncture and nutrition guidance with easing treatment side effects and aided in remission.
August 13th 2025, 7:00pm
Among patients with advanced gastrointestinal stromal tumors, Gleevec and Mektovi was associated with benefits in progression and survival.
August 13th 2025, 5:00pm
By Tamron Little
When I was diagnosed with peritoneal mesothelioma at 21 years old, the doctors gave me 18 months to live; that was 18 years ago.
August 13th 2025, 4:00pm
About one in six men with grade group 1 prostate cancer have higher-risk disease, showing outcomes vary and biopsy grade may underestimate risk.
Basal Cell Carcinoma Basics, From Diagnosis to Treatment
Stage 2 Cervical Cancer: Key Facts and Updates for Patients
HR+/HER2– Breast Cancer: Diagnosis and Treatment Guide
So You Want To Be A Cancer Advocate